Leaderboards/Chronic Lymphocytic Leukemia Research

Chronic Lymphocytic Leukemia Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Skye Montoya
Sylvester Comprehensive Cancer Center
2
Nathaniel J. Henning
Berkeley College
3
Yige Shen
Ruijin Hospital
4
Junya Sango
Icahn School of Medicine at Mount Sinai
5
Binyamin A. Knisbacher
Broad Institute
6
Rambabu Reddi
Weizmann Institute of Science
7
Daniel Thomalla
University of Cologne
8
Marco V. Haselager
Netherlands Center for Occupational Diseases
9
Laura Llaó Cid
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
10
Chang-Ching Lin
Southwestern Medical Center

Papers

1
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science|2024
148 cit.
2
Publication in Nature (2024) [83 citations, W4403920876]
Nature|2024
83 cit.
3
Publication in Nature Communications (2025) [13 citations, W4413051922]
Nature Communications|2025
13 cit.
4
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)
Signal Transduction and Targeted Therapy|2025
7 cit.
5
Publication in Experimental Hematology (2024) [W4402022334]
Experimental Hematology|2024
0 cit.
6
Publication in Molecular Biomedicine (2025) [W4417147343]
Molecular Biomedicine|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Géraldine Farjot
Air Liquide (France)
2
Werner Stenzelr
Charité - Universitätsmedizin Berlin
3
Alexander W. Hird
Paras Hospitals
4
Toby A. Eyre
Oxford University Hospitals NHS Trust
5
Daniel Addison
The University of Texas Southwestern Medical Center
6
Joseph Roswarski
Georgetown University
7
Olga Kolman
Siberian Federal University
8
Katharine M. Wright
Howard Hughes Medical Institute
9
Chingiz Underbayev
National Institutes of Health
10
Lesley Liu‐Bujalski
Ono Pharmaceutical (United States)

Papers

1
Ventricular arrhythmias and sudden death events following acalabrutinib initiation
Blood|2022
68 cit.
2
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology|2025
43 cit.
3
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Journal of Hematology & Oncology|2022
36 cit.
4
Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following Radiotherapy
International Journal of Radiation Oncology*Biology*Physics|2023
32 cit.
5
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline
British Journal of Haematology|2023
30 cit.
6
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity
JAMA Oncology|2023
29 cit.
7
Cardiovascular toxicities associated with bispecific T-cell engager therapy
Journal for ImmunoTherapy of Cancer|2024
28 cit.
8
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Nature Communications|2023
25 cit.
9
Selective Wee1 Inhibitors Led to Antitumor Activity <i>In Vitro</i> and Correlated with Myelosuppression
ACS Medicinal Chemistry Letters|2023
23 cit.
10
BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma
Future Oncology|2022
22 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Carlo M. Croce
The Ohio State University
2
Thomas J. Kipps
University of California San Diego
3
Riccardo Dalla‐Favera
Columbia University
4
John C. Byrd
University of Cincinnati
5
Owen N. Witte
Howard Hughes Medical Institute
6
Daniel Catovsky
Leuka
7
Michael J. Keating
The University of Texas MD Anderson Cancer Center
8
Nicholas Chiorazzi
Feinstein Institute for Medical Research
9
Michael Hallek
Integrated Oncology (United States)
10
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center

Papers

1
A microRNA expression signature of human solid tumors defines cancer gene targets
Proceedings of the National Academy of Sciences|2006
5.7k cit.
2
Frequent deletions and down-regulation of micro- RNA genes <i>miR15</i> and <i>miR16</i> at 13q14 in chronic lymphocytic leukemia
Proceedings of the National Academy of Sciences|2002
5k cit.
3
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Proceedings of the National Academy of Sciences|2004
4.1k cit.
4
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Cancer Research|2005
4.1k cit.
5
<i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2
Proceedings of the National Academy of Sciences|2005
3.5k cit.
6
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Blood|2008
3.2k cit.
7
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
Blood|1999
2.6k cit.
8
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia
New England Journal of Medicine|2005
2.4k cit.
9
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
New England Journal of Medicine|2012
2k cit.
10
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
The Lancet|2010
1.9k cit.

Reagents for Chronic Lymphocytic Leukemia Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 60

Cyclosporin A

Cited in 10 papers
#9973$116
View Evidence →
Cell Signaling Technology

PathScan® Total Sox2 Sandwich ELISA Kit

Cited in 9 papers
#7277$66,129,740
View Evidence →
Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

Cited in 9 papers
#CD1A20
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

Rab1A (D3X9S) Rabbit Monoclonal Antibody

Cited in 26 papers
#13075$161,351
View Evidence →
Cell Signaling TechnologyEvidence 66

Btk (D3H5) Rabbit Monoclonal Antibody

Cited in 12 papers
#8547$162,905
View Evidence →
Cell Signaling TechnologyEvidence 61

Cyclin D2 (D52F9) Rabbit Monoclonal Antibody

Cited in 10 papers
#3741$149,348
View Evidence →